SML0042

Lazabemide hydrate

≥97% (HPLC)

• Sinónimos: N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate
• Fórmula empírica (notación de Hill): C₈H₁₀ClN₃O · xH₂O
• Número de CAS: 103878-84-8
• Peso molecular: 199.64 (anhydrous basis)
• MDL number: MFCD20488051
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825112
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥97% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to tan
• solubility: DMSO: ≥22 mg/mL
• originator: Roche
• storage temp.: room temp
• SMILES string: O.NCCNC(=O)c1ccc(Cl)cn1
• InChI: 1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
• InChI key: JYWYNPKXSLPWGV-UHFFFAOYSA-N

Descripción

Application

Lazabemide hydrate may be used in cell signaling studies.

Biochem/physiol Actions

Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC₅₀ values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).

Lazabemide is effective in treatment of Alzheimer′s disease and in combination with nicotine replacement therapy aids in smoking cessation.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302,H319
• pcodes: P264 - P270 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Eye Irrit. 2
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable